Anticancer compositions and methods for making and using them

A method for:

• treating or ameliorating a cancer, wherein optionally the cancer is a leukemia or a myeloproliferative disorder in an individual in need thereof,
• inhibiting or slowing a leukemia progenitor cell propagation, or
• inhibiting or slowing a blast crisis chronic myeloid leukemia progenitor propagation in an individual in need thereof, or
• eliminating or reducing the numbers of pre-leukemia stem cells (pre-LSCs) in an individual in need thereof,
• reducing or eliminating the formation of leukemia stem cells (LCSs) in an individual in need thereof, or
• treating or ameliorating a myeloproliferative disorder in an individual in need thereof,
• the method comprising inhibiting the expression or activity of a Mouse Double Minute 2 homolog (MDM2) protein, message (mRNA) or gene, an APOBEC3G (A3G) protein, message (mRNA) or gene, and/or an ADAR1p150 protein, message (mRNA) or gene, by:
• (a) (i) providing or having provided an inhibitor of the expression or activity of:
• a Mouse Double Minute 2 homolog (MDM2) protein, message (mRNA) or gene,
• an APOBEC3G (A3G) protein, message (mRNA) or gene, and/or
• an ADAR1p150 protein, message (mRNA) or gene;
• and
• (ii) administering or having administered to an individual in need thereof, or administering the inhibitor to or expressing the inhibitor in a cancer cell, a leukemia cell, a leukemia stem cell (LSC) or a pre-leukemia cell stem cell (pre-LSC);
• (b) administering or having administered to an individual in need thereof, or administering or expressing in a cancer cell, a leukemia cell, a leukemia stem cell (LSC) or a pre-leukemia cell stem cell (pre-LSC), an inhibitor of the expression or activity of:
• a Mouse Double Minute 2 homolog (MDM2) protein, message (mRNA) or gene,
• an APOBEC3G (A3G) protein, message (mRNA) or gene, and/or
• an ADAR1p150 protein, message (mRNA) or gene;
• (c) inducing expression or inducing increased expression in a cancer or leukemia cell an endogenous inhibitor of the expression or activity of:
• a Mouse Double Minute 2 homolog (MDM2) protein, message (mRNA) or gene,
• an APOBEC3G (A3G) protein, message (mRNA) or gene, and/or
• an ADAR1p150 protein, message (mRNA) or gene;
• (d) expressing in a cancer cell, a leukemia cell, a leukemia stem cell (LSC) or a pre-leukemia cell stem cell (pre-LSC), a heterologous inhibitor of the expression or activity of:
• a Mouse Double Minute 2 homolog (MDM2) protein, message (mRNA) or gene,
• an APOBEC3G (A3G) protein, message (mRNA) or gene, and/or
• an ADAR1p150 protein, message (mRNA) or gene;
• or
• (e) any combination of (a) to (d).